Name: Valrubicin
Type: small molecule
Groups: approved
Indication: For the treatment of cancer of the bladder.
Accession Number: DB00385 ( APRD00662)
Description: Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder. [Wikipedia]
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Valstarsolution, concentrate40 mg/mLintravesical01-10-1998US
Valtaxinsolution40 mgintravesical23-04-2001Canada

Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients

  • No Category


Indication: For the treatment of cancer of the bladder.
Pharmacodynamics: Not Available
Mechanism of action: Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: >99%
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder/rupture perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m2.
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available


  • Endo pharmaceutical solutions inc

Dosage forms
Solution, concentrateintravesical40 mg/mL
Solutionintravesical40 mg

Unit descriptionCostUnit
Valstar 40 mg/ml vial$219.96ml

CountryPatent NumberApprovedExpires (estimated)


Drug Interactions

Food Interactions:
  • Not Available


Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Acetals
  • Alkyl aryl ethers
  • Alkyl fluorides
  • Alpha-acyloxy ketones
  • Alpha-hydroxy ketones
  • Amino sugars
  • Anisoles
  • Anthraquinones
  • Aryl ketones
  • Carboxylic acid esters
  • Fatty acid esters
  • Hydrocarbon derivatives
  • Hydroquinones
  • Monocarboxylic acids and derivatives
  • Monosaccharides
  • Organofluorides
  • Organonitrogen compounds
  • Oxacyclic compounds
  • Oxanes
  • Polyols
  • Secondary alcohols
  • Secondary carboxylic acid amides
  • Tertiary alcohols
  • Tetracenequinones
  • Tetralins
  • Vinylogous acids

  • 1,4-anthraquinone
  • 9,10-anthraquinone
  • Acetal
  • Alcohol
  • Alkyl aryl ether
  • Alkyl fluoride
  • Alkyl halide
  • Alpha-acyloxy ketone
  • Alpha-hydroxy ketone
  • Amino saccharide
  • Amino sugar
  • Anisole
  • Anthracene
  • Anthracycline
  • Anthracyclinone-skeleton
  • Aromatic heteropolycyclic compound
  • Aryl ketone
  • Benzenoid
  • Carbonyl group
  • Carboxamide group
  • Carboxylic acid amide
  • Carboxylic acid derivative
  • Carboxylic acid ester
  • Ether
  • Fatty acid ester
  • Fatty acyl
  • Hydrocarbon derivative
  • Hydroquinone
  • Ketone
  • Monocarboxylic acid or derivatives
  • Monosaccharide
  • Organofluoride
  • Organohalogen compound
  • Organoheterocyclic compound
  • Organonitrogen compound
  • Organooxygen compound
  • Oxacycle
  • Oxane
  • Polyol
  • Secondary alcohol
  • Secondary carboxylic acid amide
  • Tertiary alcohol
  • Tetracenequinone
  • Tetralin
  • Vinylogous acid


Synthesis Reference: Francesca Scarpitta, Csilla Nemethne Racz, "Crystalline forms of valrubicin and processes for their preparation." U.S. Patent US20080139490, issued June 12, 2008.
General Reference: Not Available
External Links:

ATC Codes:
  • Array

AHFS Codes:
  • 10:00.00

MSDS: Download

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.


The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.


Log in with your credentials

Forgot your details?